Subjective Outcomes Measurement and Regulatory Oversight for Deep Brain Stimulation in Parkinson's Disease

AJOB Neuroscience

Volumn 2, Issue 1, 2011, Pages 16-18

  Mathieu, Ghislaine ^a   Bell, Emily ^b   Racine, Eric ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551494445     PISSN: 21507740     EISSN: 21507759     Source Type: Journal    
DOI: 10.1080/21507740.2010.537535     Document Type: Article

References (16)

1. Bell, E., G. Mathieu, and E. Racine. 2009. Preparing the ethical future of deep brain stimulation. Surgical Neurology 72(6): 577-586.
2. Bell, E., B. Maxwell, M. P. MacAndrews, A. Sadikot, and E. Racine. 2010. Hope and patient expectation in deep brain stimulation: Healthcare provider perspectives and approaches. Journal ofClinical Ethics 21(2): 113-125.
3. Food and Drug Administration. 2009. Guidance for industry: Patientreported outcome measures: Use in medical product development to support labelling claims. US Department of Health and Human Services, Silver Spring, MD. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments
4. Health Canada. 2007. Underutilization of the adverse reaction reporting system. Health Canada, Government of Canada, Ottawa, ON. http://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2007/385-06/index.html
5. Holloway, R. G. 2010. Bringing the patient's voice into the measures we use. Neurology Today 10(6): 3.
6. Lasch, K. E., P. Marquis, M. Vigneux, L. Abetz, B. Arnould, M. Bayliss, B. Crawford, and K. Rosa. 2010. PRO development: Rigorous qualitative research as the crucial foundation. Quality of Life Research 19(8): 1087-1096.
7. Leidy, N. K., and M. Vernon. 2008. Perspectives on patient-reported outcomes. Pharmacoeconomics 26(5): 363-370.
8. Mahomed, N. N., K. Syed, C. B. Sledge, T. A. Brennan, and M. H. Lians. 2008. Improving the postmarket surveillance of total joint arthroplasty devices. Open Rheumatology Journal 2: 7-12.
9. Mehran, R., M. B. Leon, D. A. Feigal, D. Jefferys, M. Simons, N. Chronos, T. J. Fogarty, R. E. Kuntz, D. S. Bail, and A.V. Kaplan. 2004. Post-market approval surveillance:Acall for amore integrated and comprehensive approach. Circulation 109(25): 3073-3077.
10. Müller, S., and M. Christen. 2011. Deep brain stimulation in parkinsonian patients-Ethical evaluation of cognitive, affective, and behavioral sequelae. AJOB Neuroscience 2(1): 3-13.
11. Perez, L., J. Huang, L. Jansky, C. Nowinski, D. Victorson, A. Peterman, and D. Cella. 2007. Using focus groups to inform the Neuro-QOL measurement tool: Exploring patient-centered, health-related quality of live concepts across neurological conditions. Journal of Neuroscience Nursing 39(6): 342-353.
12. Playford, D. 2008. Outcome measurement in neurological disease. Current Opinion in Neurology 21(6): 649-653.
13. Randall, H. 2001. Port-marketing surveillance and vigilance for medical devices. The European approach. Drug Safety 24(12): 869-872.
14. Schüpbach, M., M. Gargiulo, M. L. Welter, L. Mallet, C. Béhar, J. L. Houeto, D. Maltete, V. Mesnage, and Y. Agid. 2006. Neurosurgery in Parkinson disease:Adistressedmind in a repaired body? Neurology 66(12): 1811-1816.
15. Synofzik, M., and T. E. Schlaepfer. 2008. Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnology Journal 3(12): 1511-1520.
16. World Health Organization. 2010. Clinical evidence for medical devices: Regulatory processes focussing on Europe and the United States of America. Managing the mismatch. Background Paper 3. 8 August. http://whqlibdoc.who.int/hq/2010/WHOHSS/EHT/DIM/10.8eng.pdf